Phase I-II study of concurrent irradiation and multi-drug chemotherapy in advanced carcinoma of the breast: a pilot study by the Southeastern Cancer Study Group

Conference · Wed Aug 01 04:00:00 EDT 1979 · Int. J. Radiat. Oncol., Biol. Phys.; (United States)

OSTI ID:5236627

Perez, C A; Presant, C; Philpott, G; Ratkin, G

A pilot study was begun by SECSG in October, 1976 for the treatment of patients with advanced inoperable carcinoma of the breast (stage T3-T4, N2-N3) without distant metastasis. Two courses of chemotherapy (5-FU, cytoxan, Adriamycin) are given on days 1 and 28, and after two weeks rest the radiation therapy begins. During the radiation therapy the Adriamycin is discontinued and the 5-FU and cytoxan are given at 60% of the initial dose. Two weeks after the completion of the radiotherapy, the three drugs are reinstated at the initial dose. Cycles are repeated every 28 days for a total of eight after radiotherapy (total one year therapy). The total maximum dose of Adriamycin allowable is 450 mm/m/sup 2/. Radiation therapy in doses of 6500 rad TD to the primary tumor, 6000 rad to the palpable lymph nodes and 4500 rad to electively treated lymph node bearing areas is administered using 4 MeV photons and for the internal mammary nodes 13 MeV electrons. The daily tumor dose is 180 rad, five weekly fractions. A total of 14 patients were entered to the study, five with a diagnosis of inflammatory carcinoma of the breast, five patients with advanced inoperable ductal carcinoma and four with isolated recurrences in the chest wall following a modified radical mastectomy. The primary tumor showed partial regression (50 to 75%) in 65% of the patients following the completion of the radiotherapy. Of the ten patients treated for primary carcinoma of the breast, five are alive without evidence of tumor; only two patients have developed chest wall recurrence, one of them in the posterior chest wall, behind the radiation portals.

• Research Organization: Washington Univ. School of Medicine, St. Louis, MO
• OSTI ID: 5236627
• Conference Information: Journal Name: Int. J. Radiat. Oncol., Biol. Phys.; (United States) Journal Volume: 5:8
• Country of Publication: United States
• Language: English

Related Subjects

550603 -- Medicine-- External Radiation in Therapy-- (1980-)
560151* -- Radiation Effects on Animals-- Man
62 RADIOLOGY AND NUCLEAR MEDICINE
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
ALKYLATING AGENTS
ANTIBIOTICS
ANTIMETABOLITES
ANTIMITOTIC DRUGS
AZINES
BIOLOGICAL EFFECTS
BIOLOGICAL RADIATION EFFECTS
BODY
CARCINOMAS
DISEASES
DOSES
DOXORUBICIN
DRUGS
ENDOXAN
FLUOROURACILS
FRACTIONATED IRRADIATION
GLANDS
HETEROCYCLIC COMPOUNDS
HYDROXY COMPOUNDS
IRRADIATION
LOCAL IRRADIATION
LYMPH NODES
LYMPHATIC SYSTEM
MAMMARY GLANDS
NEOPLASMS
ORGANIC COMPOUNDS
ORGANIC FLUORINE COMPOUNDS
ORGANIC HALOGEN COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
ORGANS
PATIENTS
PYRIMIDINES
RADIATION EFFECTS
RADIOSENSITIVITY EFFECTS
RESPONSE MODIFYING FACTORS
URACILS